Joshua Feiner, MD
Endocrinology, Diabetes & Metabolism · Bethpage, NYNPI 1750560421
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 93.8% of the total across 255 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 42 manufacturers, the largest accounting for just 12.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,696, 3.6 times the $472 reported in 2019.
Across 255 payments — averaging $20.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$633
- Abbott$466
- Novo Nordisk$373
- Lilly USA, LLC$332
- Xeris Pharmaceuticals, Inc.$320
- Medtronic$266
- plus $3K from 36 others
What the payments were for
- Speaking & faculty fees$2555%
- Food & beverage$4,93394%
- Education$691%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,257 in reported general payments places this provider in the 75th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 410 | $837,042 |
| MounjaroTirzepatide | 253 | $509,129 |
| TrulicityDulaglutide | 216 | $390,818 |
| JardianceEmpagliflozin | 212 | $310,064 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 133 | $192,269 |
| FarxigaDapagliflozin Propanediol | 117 | $154,728 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 69 | $102,177 |
| JanuviaSitagliptin Phosphate | 87 | $90,718 |
| Tresiba Flextouch U-100Insulin Degludec | 102 | $90,133 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 55 | $66,741 |
| TradjentaLinagliptin | 42 | $46,730 |
| Xigduo XrDapaglifloz Propaned/Metformin | 28 | $42,089 |
| Novolog FlexpenInsulin Aspart | 92 | $35,038 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $33,763 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 28 | $31,564 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $332 | $899,946469 claims |
| Novo NordiskOzempic, Novolog | $373 | $848,403441 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta, Synjardy, Jentadueto Xr | $211 | $490,627347 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $181 | $192,269133 claims |
| MerckJanuvia, Janumet Xr | $173 | $157,459142 claims |
| AstraZenecaFarxiga | $89 | $154,728117 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $188 | $12,769835 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Bethpage
- Craig PerlmanBethpage$69K
- Robert BuschAlbany$2.7M
- Michael ShanikSmithtown$1.2M
- Ajay ChaudhuriBuffalo$888K
- Vinay KapoorManhasset$820K
- John BilezikianNew York$809K
- Barbara HirschManhasset$746K
- Martin GrajowerBronx$713K
- Anastasios ManessisNew York$656K
- Jonas LeibowitzYonkers$613K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.